$5.74
-2.0%LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Last Annual Value
40.57M
3-Year CAGR
53%
5-Year CAGR
37%
10-Year CAGR
18%
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() LENSAR, Inc. NASDAQ:LNSR | 40.57M | 51.7% | 36.0% | N/A | |
![]() Cardiff Oncology, Inc. NASDAQ:CRDF | 16.39M | 16.2% | 20.1% | 7.7% | |
![]() TriSalus Life Sciences, Inc. NASDAQ:TLSI | 11.50M | -7.8% | 12.5% | N/A | |
![]() Sight Sciences, Inc. NASDAQ:SGHT | 11.03M | -3.5% | -4.0% | N/A | |
![]() Apyx Medical Corporation NASDAQ:APYX | 11.70M | -2.8% | -2.4% | 8.3% | |
![]() Hyperfine, Inc. NASDAQ:HYPR | 11.73M | 10.2% | -5.7% | N/A | |
![]() Lucid Diagnostics Inc. NASDAQ:LUCD | 28.58M | -0.9% | 46.3% | N/A | |
![]() AVITA Medical, Inc. NASDAQ:RCEL | 62.68M | 68.1% | 47.0% | 37.8% | |
![]() Spero Therapeutics, Inc. NASDAQ:SPRO | 8.87M | -38.0% | -13.8% | 2.5% | |
![]() Rapid Micro Biosystems, Inc. NASDAQ:RPID | 18.49M | -0.9% | 0.4% | N/A | |
![]() Owlet, Inc. NYSE:OWLT | 44.20M | -0.7% | -8.5% | N/A |
Continue your LNSR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.